Australian drug discovery and development company Alchemia ltd today said it has entered into an agreement for sale of exclusive intellectual property rights of fondaparinux sodium to Dr Reddy's laboratories (DRl), for $17.5 million (about `115.6 crore).
Fondaparinux is a generic version of the anticoagulant drug Arixtra which is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also indicated for prevention of DVT after major surgery, such as knee and hip replacement worldwide.